Merrimack Pharmaceuticals Updates Timing of Third Quarter 2013 Investor Conference Call

CAMBRIDGE, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Third Quarter 2013 Investor Conference call at 8 a.m. Eastern time on Thursday, November 7. The call had previously been scheduled for later in the morning on November 7. Merrimack moved the call as a courtesy to the investment community to avoid overlap with the release of abstracts from a major medical meeting.

The call will cover an update on Merrimack's progress as well as a summary of third quarter financials. A press release detailing the information to be discussed on the call will be issued prior to the call on the morning of Thursday, November 7. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 92590100.

Slides accompanying the call and a listen-only webcast of the call can be accessed in the Investors section of Merrimack's website, http://investors.merrimackpharma.com, and a replay of the call will be archived there for six weeks.

About Merrimack

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com.

Forward-looking statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT: Investor Contact: Geoffrey M. Grande, CFA Investor Relations Merrimack Pharmaceuticals 617-441-7602 ggrande@merrimackpharma.com Media Contact: Dana Robie Corporate Communications Merrimack Pharmaceuticals 617-441-7408 drobie@merrimackpharma.comSource:Merrimack Pharmaceuticals